A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease

NCT06189495 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Sclerosis Associated Interstitial Lung Disease
Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD)
Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

Interventions

DRUG: GenSci048
DRUG: GenSci048 placebo

Sponsor

Changchun GeneScience Pharmaceutical Co., Ltd.

Collaborators

[object Object]